CNS lymphoma · 12 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Bu/TT Variant #01 Partial | — | R 28 006 | — | — | — | ~1 | ~R 28 006 indirect | — |
Bu/TT/Cy Variant #01 Partial | — | R 9 578 | — | — | — | ~1 | ~R 9 578 indirect | — |
Cytarabine and Etoposide (CYVE) Variant #06 | — | R 4 351 | — | — | ~9.2 mo | ~2 | ~R 8 701 PFS proxy · indirect | — |
BEAM Variant #01 Partial | — | R 4 346 | — | — | — | ~1 | ~R 4 346 indirect | — |
High-dose Cytarabine monotherapy (HiDAC) Variant #01 | — | R 3 498 | — | ~5.2 mo | — | ~1 | ~R 3 498 PFS proxy · indirect | 1 |
Temozolomide monotherapy Variant #02 | — | R 3 434 | 14d | ~4.0 mo | ~16.3 mo | ~27 | ~R 92 712 PFS proxy · indirect | 10 |
Lomustine, Methotrexate, Procarbazine Variant #01 Partial | — | R 609 | 45d | — | — | ~3 | ~R 1 826 indirect | — |
BCNU/TT Variant #01 Partial | — | — | — | — | — | ~1 | — | — |
Procarbazine monotherapy Variant #01 Partial | — | — | 28d | — | — | ~6 | — | — |
Whole brain irradiation N/A - radiation | — | — | 21d | — | — | — | — | 1 |
Methotrexate monotherapy Partial | — | — | — | ~2.6 mo | ~6.7 mo | — | — | 10 |
Observation Partial | — | — | — | — | 37.1 mo | — | — | 1 |
12 of 12 regimens shown